Brenda Jesernig

Brenda Jesernig's work experience includes roles at Lyell Immunopharma, Apex Systems, and Fred Hutch.

At Lyell Immunopharma, they currently hold the position of Scientist I since October 2022. Prior to that, they served as a Senior Research Associate from November 2019 to October 2022.

At Apex Systems, Brenda worked as a Senior Research Associate Consultant at Juno Therapeutics from February 2019 to November 2019. Their responsibilities involved testing the safety profile of bi- and tri-specific antibodies directed at AML and MM targets, conducting cytotoxicity tests, and performing flow cytometry for proliferation validation and cell subset sorting.

Their earliest role was at Fred Hutch, where they worked as a Research Technician III from May 2015 to February 2019. In this position, they focused on developing personalized cancer neoantigen vaccines and discovering T cell receptors specific to driver mutations in lung and melanoma patients.

Overall, Brenda has gained extensive experience in scientific research and development, with a focus on immunotherapy and cancer vaccines.

Brenda Jesernig earned their Bachelor's degree in Biology, General from Washington State University Global Campus. Brenda continued their education at Washington State University Graduate School, where they pursued a Master of Science - MS in Animal Sciences from 2013 to 2015.